Replies to post #501857 on Zeev's Turnips Patch-No Politics (ZEEV)

[redwards]

interesting: HDAC Inhibitors:
Unraveling Cancer Cells
Inhibitors of histone deacetylase (HDAC) enzymes have received increasing attention from researchers examining new ways to target cancer cells without harming normal tissue. In the cell nucleus, DNA is present with proteins as part of a tightly compacted complex called chromatin. HDAC enzymes play a role in modifying the structure of chromatin, allowing DNA transcription – a process by which DNA controls cellular activity – to occur. HDAC inhibitors appear to alter the transcription process.

HDAC inhibitors target tumors through multiple mechanisms, and laboratory studies have shown that they can prompt cells to stop growing or die. This may happen through the expression of tumor suppressor genes, the prevention of angiogenesis and the targeting of various critical proteins.

Pharmacyclics' HDAC Program:
PCI-24781: Pharmacyclics' lead HDAC inhibitor, PCI-24781 is now being evaluated in a Phase 1 clinical trial. The drug targets all forms of HDAC, broadening the number of tumors sensitive to the drug. The study is designed to assess the safety and tolerability of an intravenous formulation of the drug, as well as to determine the maximum tolerated dose.

In addition, the trial will explore the effect of the drug on new biomarkers, which will help researchers better understand how this therapy works and better evaluate its effectiveness.

http://www.pharmacyclics.com/wt/page/hdac

((just doing early DD)
18-Sep-06 DUGGAN, ROBERT W.
Beneficial Owner (10% or more) 17,742 Direct Purchase at $4.75 per share. $84,274
8-Sep-06 DUGGAN, ROBERT W.
Beneficial Owner (10% or more) 4,112 Direct Purchase at $4.80 per share. $19,737
7-Sep-06 DUGGAN, ROBERT W.
Beneficial Owner (10% or more) 19,036 Direct Purchase at $4.50 - $4.65 per share. $87,0002
6-Sep-06 DUGGAN, ROBERT W.
Beneficial Owner (10% or more) 3,999 Direct Purchase at $4.47 - $4.56 per share. $18,0002
5-Sep-06 DUGGAN, ROBERT W.
Beneficial Owner (10% or more) 36,696 Direct Purchase at $4.43 - $4.5 per share. $164,0002
1-Sep-06 DUGGAN, ROBERT W.
Beneficial Owner (10% or more) 20,100 Direct Purchase at $4.31 - $4.57 per